Longeveron (LGVN) investor relations material

Executive summary

• Initiated a strategic repositioning to a capital-efficient, asset-light model, emphasizing licensing partnerships for laromestrocel across HLHS, Alzheimer's, PDCM, and aging-related frailty programs.

• Completed a private placement in March 2026, raising $15.9 million and extending cash runway into Q4 2026, but substantial doubt remains about ability to continue as a going concern without further capital.

• No FDA-approved products; revenue is derived from clinical trial participation and contract manufacturing, both limited and declining.

• Attracted new investment from leading life sciences funds and implemented cash-saving measures to extend operational runway.

• Engaged in ongoing regulatory discussions with the FDA for HLHS and Alzheimer's, with plans for immediate post-readout meetings and a pre-BLA meeting in 2027.

Financial highlights

• Q1 2026 revenues were $0.4 million, flat year-over-year; clinical trial revenue increased 46% while contract manufacturing revenue declined 84%.

• General and administrative expenses decreased 7% to $2.7 million, and R&D expenses decreased 8% to $2.3 million, both due to lower personnel costs and non-recurring charges.

• Net loss for Q1 2026 was $4.7 million, a 6% improvement from $5 million in Q1 2025.

• Cash and cash equivalents stood at $15.8 million as of March 31, 2026, expected to fund operations into Q4 2026.

• Gross profit remained flat at $0.3 million for both Q1 2026 and Q1 2025.

Outlook and guidance

• Top-line results from the ELPIS II trial in HLHS are anticipated in August 2026, with immediate plans to engage the FDA for next steps and potential BLA filing.

• Preparation for a phase II registrational trial in PDCM is underway, with study initiation targeted for 2027.

• Current cash is expected to fund operations into Q4 2026; additional capital will be required to continue development and commercialization efforts.

• Actively seeking strategic partnerships and non-dilutive funding, especially for the Alzheimer's program.

• A second private placement closing is contingent on achieving clinical milestones.